Evidence of an autocrine role for leptin and leptin receptor in human breast cancer

Cancer Genomics and Proteomics

Volumn 9, Issue 6, 2012, Pages 383-388

  Wazir, Umar ^a,b   Al Sarakbi, Wael ^a   Jiang, Wen G ^c   Mokbel, Kefah ^a,b  

^a Princess Grace Hospital   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Autocrine; Autophagy; Breast cancer; Breast cell lines; COX2; hTERT; Leptin; MCF7; MDA436; qPCR

Indexed keywords

CYCLOOXYGENASE 2; LEPTIN; LEPTIN RECEPTOR; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS;

EID: 84869740357     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9: 6432-6440, 2003.
2. Brobeck JR: Mechanism of the development of obesity in animals with hypothalamic lesions. Physiol Rev 26: 541-559, 1946.
3. Hervey GR: The effects of lesions in the hypothalamus in parabiotic rats. J Physiol 145: 336-352, 1959.
4. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK and Friedman JM: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269: 543-546, 1995.
5. Gotoda T, Manning BS, Goldstone AP, Imrie H, Evans AL, Strosberg AD, McKeigue PM, Scott J and Aitman TJ: Leptin receptor gene variation and obesity: Lack of association in a white British male population. Hum Mol Genet 6: 869-876, 1997.
6. Zerani M, Boiti C, Dall'Aglio C, Pascucci L, Maranesi M, Brecchia G, Mariottini C, Guelfi G, Zampini D and Gobbetti A: Leptin receptor expression and in vitro leptin actions on prostaglandin release and nitric oxide synthase activity in the rabbit oviduct. J Endocrinol 185: 319-325, 2005.
7. Hu X, Juneja SC, Maihle NJ and Cleary MP: Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 94: 1704-1711, 2002.
8. Saxena NK, Ikeda K, Rockey DC, Friedman SL and Anania FA: Leptin in hepatic fibrosis: Evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology 35: 762-771, 2002.
9. Bohlender J, Rauh M, Zenk J and Groschl M: Differential distribution and expression of leptin and the functional leptin receptor in major salivary glands of humans. J Endocrinol 178: 217-223, 2003.
10. Green ED, Maffei M, Braden VV, Proenca R, DeSilva U, Zhang Y, Chua SC Jr., Leibel RL, Weissenbach J and Friedman JM: The human obese (OB) gene: RNA expression pattern and mapping on the physical, cytogenetic, and genetic maps of chromosome 7. Genome Res 5: 5-12, 1995.
11. Friedman JM: Leptin, leptin receptors, and the control of body weight. Nutr Rev 56: s38-46; discussion s54-75, 1998.
12. Kim HS: Leptin and leptin receptor expression in breast cancer. Cancer Res Treat 41: 155-163, 2009.
13. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF and Adam HO: A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 12: 13-21, 2001.
14. Paz-Filho G, Lim EL, Wong ML and Licinio J: Associations between adipokines and obesity-related cancer. Front Biosci 16: 1634-1650, 2011.
15. Davis AA and Kaklamani VG: Metabolic syndrome and triple-negative breast cancer: A new paradigm. Int J Breast Cancer 2012: 809291, 2012.
16. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzua P, Vatner SF and Rabson AB: Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis 32: 1381-1387, 2011.
17. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, Yang X and Tian B: Serum levels of leptin, insulin, and lipids in relation to breast cancer in China. Endocrine 26: 19-24, 2005.
18. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, Yu JC and Sun CA: Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer 100: 578-582, 2009.
19. Kim Y, Kim SY, Lee JJ, Seo J, Kim YW, Koh SH, Yoon HJ and Cho KS: Effects of the expression of leptin and leptin receptor (OBR) on the prognosis of early-stage breast cancers. Cancer Res Treat 38: 126-132, 2006.
20. Xia XH, Gu JC, Bai QY and Yu W: Overexpression of leptin and leptin receptors in breast cancer positively correlates with clinicopathological features. Chin Med J (Engl) 122: 3078-3081, 2009.
21. Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, Shimomura I and Noguchi S: High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. Int J Cancer 118: 1414-1419, 2006.
22. Liu C and Liu L: Polymorphisms in three obesity-related genes (LEP, LEPR, and PON1) and breast cancer risk: A metaanalysis. Tumour Biol 32: 1233-1240, 2011.
23. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Helal AN and Chouchane L: Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer 6: 38, 2006.
24. Artac M, Bozcuk H, Kiyici A, Eren OO, Boruban MC and Ozdogan M: Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs). Breast Cancer 2011 (Online First).
25. Karaduman M, Bilici A, Ozet A, Sengul A, Musabak U and Alomeroglu M: Tissue leptin levels in patients with breast cancer. J Balkan Union Onc 15: 369-372, 2010.
26. Jarde T, Caldefie-Chezet F, Damez M, Mishellany F, Penault-Llorca F, Guillot J and Vasson MP: Leptin and leptin receptor involvement in cancer development: A study on human primary breast carcinoma. Oncol Rep 19: 905-911, 2008.
27. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D and Anania FA: Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67: 2497-2507, 2007.
28. Elkak A, Mokbel R, Wilson C, Jiang WG, Newbold RF and Mokbel K: hTERT mRNA expression is associated with a poor clinical outcome in human breast cancer. Anticancer Res 26: 4901-4904, 2006.
29. Ren H, Zhao T, Wang X, Gao C, Wang J, Yu M and Hao J: Leptin up-regulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Biophys Res Commun 394: 59-63, 2010.
30. Rahmati-Yamchi M, Zarghami N, Rahbani M and Montazeri A: Plasma leptin, hTERT gene expression, and anthropometric measures in obese and non-obese women with breast cancer. Breast Cancer (Auckl) 5: 27-35, 2011.
31. Rodrigues S, Bruyneel E, Rodrigue CM, Shahin E and Gespach C: Cyclooxygenase 2 and carcinogenesis. Bull Cancer 91(Suppl 2): S61-76, 2004 (in French).
32. Howe LR, Subbaramaiah K, Brown AM and Dannenberg AJ: Cyclooxygenase-2: A target for the prevention and treatment of breast cancer. Endocr Relat Cancer 8: 97-114, 2001.
33. Hsieh PS, Lu KC, Chiang CF and Chen CH: Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats. Eur J Clin Invest 40: 164-171, 2010.
34. Singh B, Cook KR, Vincent L, Hall CS, Berry JA, Multani AS and Lucci A: Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 147: 240-246, 2008.
35. van Nes JG, de Kruijf EM, Faratian D, van de Velde CJ, Putter H, Falconer C, Smit VT, Kay C, van de Vijver MJ, Kuppen PJ and Bartlett JM: COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125: 671-685, 2011.
36. Kim HS, Moon HG, Han W, Yom CK, Kim WH, Kim JH and Noh DY: COX2 overexpression is a prognostic marker for stage III breast cancer. Breast Cancer Res Treat 132: 51-59, 2012.
37. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L and Cristofanilli M: Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117: 61-68, 2009.
38. Singh B, Berry JA, Shoher A and Lucci A: COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 131: 267-275, 2006.
39. Flowers M and Thompson PA: t10c12-Conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: Possible role of COX2. PLoS ONE 4: e5342, 2009.
40. Kwan ML, Habel LA, Slattery ML and Caan B: NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18: 613-620, 2007.
41. Guastalla JP, Bachelot T and Ray-Coquard I: Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials. Bull Cancer 91 Spec No: S99-108, 2004 (in French).
42. Arun B and Goss P: The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31: 22-29, 2004.
43. Liu B, Wen JK, Li BH, Fang XM, Wang JJ, Zhang YP, Shi CJ, Zhang DQ and Han M: Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms. Cell Death Dis 2: e185, 2011.